Wang Xin
Clinical trials sponsored by Wang Xin, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Precision radiation plus immunotherapy shows promise for bile duct cancer Results expected Sep 2026 (estimated)
-
Can a Triple-Drug induction boost anal cancer remission?
Disease control Not yet recruitingThis phase 2 trial tests whether adding the investigational drug becotatug vedotin to pucotenlimab and capecitabine before standard chemoradiotherapy can improve outcomes for people with locally advanced squamous cell carcinoma of the anal canal. Participants first receive two cy…
Phase 2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Triple therapy aims to wipe out rectal cancer before surgery
Disease control Not yet recruitingThis phase II trial tests a new approach for high-risk locally advanced rectal cancer. Participants first receive short-course radiotherapy, followed by a combination of chemotherapy (NALIRIFOX) and immunotherapy (Pucotenlimab) for about 6 months. The goal is to see if this regim…
Phase 2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC